Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Oxford | OTHER |
Not provided
Not provided
Not provided
The goal of this clinical trial is to determine if a complex intervention called SMARThealth Pregnancy can improve the detection and management of high-risk conditions during pregnancy and in the first year after birth in women living in rural India.
The main questions it aims to answer are:
The primary aim of this study is to determine if the SMARThealth Pregnancy intervention can improve women's health in the year after pregnancy, specifically decrease the prevalence of anaemia by 9% and improve follow-up after a pregnancy affected by diabetes or hypertension. High glucose and blood pressure are the two leading contributors to cardiometabolic risk in women in India, thus it is hypothesised that targeting women identified in pregnancy at high risk of these conditions future risk can be decreased.
This study hypothesize SMARThealth Pregnancy intervention will:
Recruitment commenced in Siddipet district 6 June 2022 and will commence in Haryana 1 January 2023.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SMARThealth Pregnancy | Experimental | SMART Health Pregnancy is a complex intervention designed to be delivered on top of usual care. It comprises three parts: (i) A regular screening program focused on women's health during pregnancy and in the year following birth. (ii) An electronic decision support system (EDSS) (iii) An short messaging service (SMS) appointment reminder system |
|
| Active Comparator: Usual Care | No Intervention | Usual antenatal and postnatal care. Women and health workers in the usual care clusters will not receive any additional support beyond that already offered under the local government programs |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SMARThealth Pregnancy | Other | At each visit, the CHW will:
An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:
|
| Measure | Description | Time Frame |
|---|---|---|
| Change anaemia prevalence in women | Proportion of participants with any degree of anaemia (non-pregnant definition Hb < 12g/dL) between the intervention and control clusters | 10-12 months after delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Change the proportion of women with moderate and severe anaemia | Proportion of participants with moderate anaemia (Hb < 10g /dL) and severe anaemia (Hb < 8g /dL) between the intervention and control clusters | 10-12 months after delivery |
| Postnatal screening for type 2 diabetes after GDM |
| Measure | Description | Time Frame |
|---|---|---|
| Differences in quality of life scores | Differences in EuroQuol 5D (EQ5D) score between baseline and at 12 months. The Five-item EQID uses scale of health score from 0 (worst imaginable) to 100 (best imaginable) | 10-12 months after delivery |
| Differences in depression scores |
Inclusion Criteria:
For Primary health Centres:
For women >12 weeks pregnant
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jane E Hirst, MBBS MPH PhD | University of Oxford | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The George Institute for Global Health | Hyderabad | Telangana | 500082 | India |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34816187 | Background | Nagraj S, Kennedy SH, Jha V, Norton R, Hinton L, Billot L, Rajan E, Arora V, Praveen D, Hirst JE. SMARThealth Pregnancy: Feasibility and Acceptability of a Complex Intervention for High-Risk Pregnant Women in Rural India: Protocol for a Pilot Cluster Randomised Controlled Trial. Front Glob Womens Health. 2021 May 28;2:620759. doi: 10.3389/fgwh.2021.620759. eCollection 2021. | |
| 37559158 |
| Label | URL |
|---|---|
| Study website | View source |
Not provided
All de-identified individual data and data dictionary will be made available for sharing on the day of publication of the main results.
Data will be made available through a 3rd party data repository, via email request to the Principal Investigator on receipt of a signed data sharing agreement.
Data will become available after publication of the main study findings and will be available for an indefinite period of time
Data will be made available through a 3rd party data repository, via email request to the Principal Investigator on receipt of a signed data sharing agreement
Not provided
Not provided
Cluster randomised trial
Not provided
Not provided
Double (Investigator, Outcomes Assessor) The investigator and outcomes assessor will be blinded to allocation group. Each cluster will be coded and using a random number generator. The sites will only be unlinked after final database lock after endpoint adjudication for analysis.
|
Proportion of women with GDM who undergo screening for type 2 diabetes in the first year after delivery |
| 10-12 months after delivery |
| Postnatal screening for hypertension after hypertensive disorder of pregnancy | Proportion of women with a hypertensive disorder of pregnancy screened for hypertension in the first year after delivery | 10-12 months after delivery |
| Compliance with iron-folic acid supplements during pregnancy and breastfeeding | Self reported compliance with iron folic acid supplementation | 10-12 months after delivery |
| De-worming treatment | Proportion of women during pregnancy who receive de-worming treatment | during pregnancy |
| Point of care Haemoglobin (Hb) testing | Proportion of women who have a point of care Hb test during pregnancy and in the post natal period | 10-12 months after delivery |
| Referral of high risk conditions | The proportion of women detected with anaemia, hypertension or GDM correctly referred to primary or secondary care | Six weeks post delivery |
| Hypertension after hypertensive disorder of pregnancy | Differences in systolic and diastolic blood pressure in women who were diagnosed during pregnancy with hypertensive disorder of pregnancy | 10-12 months after delivery |
| Dysglycaemia after a pregnancy affected by GDM | Difference in HbA1c, fasting and 2-hour glucose venous samples post 75 gram glucose load in those who developed GDM during pregnancy | 10-12 months after delivery |
Differences in Patient Health Questionnaire 9 (PHQ9) scores between baseline and at 12 months. Nine-item PHQ-9 use 4-point Likert-scaled items ranging from 0 (not at all) to 3 (nearly every day). |
| 10-12 months after delivery |
| Differences in anxiety scores | Differences in Generalised Anxiety and Depression score 7 (GAD7) scores between baseline and at 12 months. The seven-item GAD-7 use 4-point Likert-scaled items ranging from 0 (not at all) to 3 (nearly every day). | 10-12 months after delivery |
| Infant feeding | World Health Organization Infant and Young Feeding Assessment | 6 weeks after delivery and 12 months after delivery] |
| Pregnancy intention | Difference in London Measure of Unplanned pregnancy scores | 10-12 months post natal |
| Cost of care | Direct and indirect costs of care during pregnancy and for the first six weeks after birth | 6 - 10 weeks after birth |
| Derived |
| Hirst JE, Votruba N, Billot L, Arora V, Rajan E, Thout SR, Peiris D, Patel A, Norton R, Mullins E, Sharma A, Kennedy S, Jha V, Praveen D. A community-based intervention to improve screening, referral and follow-up of non-communicable diseases and anaemia amongst pregnant and postpartum women in rural India: study protocol for a cluster randomised trial. Trials. 2023 Aug 9;24(1):510. doi: 10.1186/s13063-023-07510-x. |
| ID | Term |
|---|---|
| D016640 | Diabetes, Gestational |
| D046110 | Hypertension, Pregnancy-Induced |
| D011225 | Pre-Eclampsia |
| D000740 | Anemia |
| D003924 | Diabetes Mellitus, Type 2 |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided